Multiple Sclerosis Clinical Trial

Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies

Summary

Vaccine responses in patients treated with anti-CD20 antibodies (ocrelizumab and ofatumumab) or S1P receptor modulators (fingolimod and siponimod) were evaluated before and after third SARS-CoV-2 vaccination as part of an ongoing longitudinal study. Total spike protein and spike receptor binding domain (RBD)-specific immunoglobulin G (IgG) responses were measured by Luminex bead-based assay. Spike-specific CD4+ and CD8+ T cell responses were measured by activation-induced marker expression.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

All Participants:

Aged 18-75 years old MS Patients
Diagnosed with MS based on 2017 McDonald criteria

Exclusion Criteria

All Participants:

Participants with a known history of COVID-19 Healthy Adults
Immunocompromised or on immunosuppressive therapy MS Patients
None specified

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

61

Study ID:

NCT05950308

Recruitment Status:

Completed

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Novartis
East Hanover New Jersey, 07936, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

61

Study ID:

NCT05950308

Recruitment Status:

Completed

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.